• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life.

作者信息

Giuliani Jacopo, Bonetti Andrea

机构信息

Department of Oncology, Mater Salutis Hospital, Legnago, Italy.

Department of Oncology, Mater Salutis Hospital, Legnago, Italy.

出版信息

Clin Colorectal Cancer. 2020 Dec;19(4):e181-e182. doi: 10.1016/j.clcc.2020.04.004. Epub 2020 Apr 23.

DOI:10.1016/j.clcc.2020.04.004
PMID:32423567
Abstract
摘要

相似文献

1
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life.曲氟尿苷/替匹嘧啶在现实生活中治疗难治性转移性结直肠癌的经济可持续性
Clin Colorectal Cancer. 2020 Dec;19(4):e181-e182. doi: 10.1016/j.clcc.2020.04.004. Epub 2020 Apr 23.
2
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.英国和威尔士既往治疗转移性结直肠癌患者中使用曲氟尿苷替匹嘧啶的成本效果分析。
Clin Colorectal Cancer. 2018 Mar;17(1):e143-e151. doi: 10.1016/j.clcc.2017.09.001. Epub 2017 Sep 28.
3
Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.新型三联疗法曲氟尿苷/替匹嘧啶联合贝伐单抗用于意大利转移性结直肠癌三线治疗的成本效益分析
Clin Colorectal Cancer. 2024 Mar;23(1):1-3. doi: 10.1016/j.clcc.2023.10.005. Epub 2023 Oct 14.
4
Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.在难治性转移性结直肠癌中进行剂量递增策略：成本效益的变化。
J Oncol Pharm Pract. 2021 Jun;27(4):974-977. doi: 10.1177/1078155221992546. Epub 2021 Feb 4.
5
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.曲氟尿苷/替匹嘧啶联合贝伐单抗一线治疗转移性结直肠癌：前进之路。基于成本效益的观点
Clin Colorectal Cancer. 2022 Jun;21(2):e145-e147. doi: 10.1016/j.clcc.2021.11.012. Epub 2021 Dec 5.
6
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.替氟尿苷/替匹嘧啶对比纳武利尤单抗治疗日本晚期转移性胃癌的成本效果分析。
Jpn J Clin Oncol. 2021 Aug 30;51(9):1383-1390. doi: 10.1093/jjco/hyab086.
7
Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.奥沙利铂联合替匹嘧啶/三氟尿苷治疗转移性结直肠癌的 I 期剂量递增研究。
Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.
8
The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.替氟尿苷他比嘧啶治疗转移性结直肠癌的安全性和有效性：药剂学视角。
Am J Health Syst Pharm. 2019 Feb 21;76(6):339-348. doi: 10.1093/ajhp/zxy006.
9
Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.曲氟尿苷/替匹嘧啶：澳大利亚难治性转移性结直肠癌治疗实用指南
Asia Pac J Clin Oncol. 2020 Apr;16 Suppl 1:3-12. doi: 10.1111/ajco.13336.
10
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.替拉鲁肽/曲氟尿苷治疗晚期难治性结直肠癌患者的生存预测：真实世界数据与临床试验数据比较。
Sci Rep. 2021 Jul 12;11(1):14321. doi: 10.1038/s41598-021-93732-5.